Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
CHICAGO, Aug. 14, 2018 /PRNewswire/ — Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.
URL link to full story
https://www.prnewswire.com/news-releases/emalex-biosciences-acquires-psyadon-pharmaceuticals-to-develop-novel-treatment-for-pediatric-tourette-syndrome-300696350.html
Media Contact
Susan Brophy
312-729-4359